Mechanisms of Amiodarone and Desethylamiodarone Cytotoxicity in Nontransformed Human Peripheral Lung Epithelial Cells
Authors:
- James F. BrienJBJames F. Brien
- William J. RaczWRWilliam J. Racz
- Takashi TakahashiTTTakashi Takahashi
- Thomas E. MasseyTMThomas E. Massey
- 1 February 2011
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 336 (2) , 551-559
Abstract
Amiodarone (AM) is a potent antidysrhythmic agent that can cause potentially life-threatening pulmonary fibrosis, and N-desethylamiodarone (DEA), an AM metabolite, may contribute to AM toxicity. Apoptotic cell death in nontransformed human peripheral lung epithelial 1A (HPL1A) cells was assessed by annexin V-fluorescein isothiocyanate (ann-V) staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), and necrotic cell death was assessed by propidium iodide (PI) staining. The percentage of cells that were PI-positive increased more than six times with 20 μM AM and approximately doubled with 3.5 μM DEA, relative to control. The percentage of cells that were ann-V-positive decreased by more than 80% after 24-h exposure to 10 μM AM but more than doubled after 24-h incubation with 3.5 μM DEA. Incubation for 24 h with 5.0 μM DEA increased the percentage of cells that were TUNEL-positive more than six times. Incubation with AM (2.5 μM) or DEA (1–2 μM) for 24 h did not significantly alter angiotensinogen mRNA levels. Furthermore, angiotensin II (100 pM–1 μM) alone or in combination with AM or DEA did not alter cytotoxicity, and pretreatment with the angiotensin-converting enzyme inhibitor and antioxidant captopril (3–6 μM) did not protect against AM or DEA cytotoxicity. In conclusion, AM activates primarily necrotic pathways, whereas DEA activates both necrotic and apoptotic pathways, and the renin-angiotensin system does not seem to be involved in AM or DEA cytotoxicity in HPL1A cells.Keywords
This publication has 33 references indexed in Scilit:
- Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicityBritish Journal of Clinical Pharmacology, 2009
- Direct mitochondrial dysfunction precedes reactive oxygen species production in amiodarone-induced toxicity in human peripheral lung epithelial HPL1A cellsToxicology and Applied Pharmacology, 2008
- Combined treatment with l-carnitine and a pan-caspase inhibitor effectively reverses amiodarone-induced injury in cultured human lung epithelial cellsApoptosis, 2008
- Long-Term Plasma Levels and Dose Modulation of Alacepril in Patients with Chronic Renal FailureHypertension Research, 2008
- Amiodarone Induces Angiotensinogen Gene Expression in Lung Alveolar Epithelial Cells through Activation Protein‐1Basic & Clinical Pharmacology & Toxicology, 2006
- Hepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone DerivativesThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Differential susceptibilities of isolated hamster lung cell types to amiodarone toxicityCanadian Journal of Physiology and Pharmacology, 1998
- Pharmacology and Pharmacokinetics of AmiodaroneThe Journal of Clinical Pharmacology, 1991
- Amiodarone-mediated increase in intracellular free Ca2+ associated with cellular injury to human pulmonary artery endothelial cellsToxicology and Applied Pharmacology, 1990
- Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissuesCanadian Journal of Physiology and Pharmacology, 1987